Results 21 to 30 of about 18,678 (212)
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
Viruses, 2023 Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We conducted
David E. Martin +6 more
doaj +1 more source
Frontiers in Molecular Neuroscience, 2022 Proinflammatory immune cell subsets constitute the majority in the local microenvironment after spinal cord injury (SCI), leading to secondary pathological injury.
Qi Qi +14 more
doaj +1 more source
Frontiers in Physiology, 2018 Background: Probenecid is a uricosuric agent that in addition to exerting a positive ionotropic effect in the heart, blocks the ATP transporter Pannexin 1 and inhibits the Cl-/HCO3- exchanger, pendrin.
Sharon Barone +9 more
doaj +1 more source
Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain [PDF]
, 2017 There is accumulating evidence that bumetanide, which has been used over decades as a potent loop diuretic, also exerts effects on brain disorders, including autism, neonatal seizures, and epilepsy, which are not related to its effects on the kidney but ...
Erker, Thomas +7 more
core +2 more sources
Therapeutic Advances in Medical Oncology, 2022 Introduction: In breast cancer patients treated with the anti-estrogen tamoxifen, low concentrations of the active metabolite endoxifen are associated with more disease recurrence.
Stefan A. J. Buck +12 more
doaj +1 more source
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. [PDF]
, 2016 BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels.
Girardet, Jean-Luc +12 more
core +2 more sources
Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
PLoS ONE, 2020 Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes.
Evan Onusko +6 more
doaj +1 more source
Spatiotemporal visualization of subcellular dynamics of carbon nanotubes [PDF]
, 2012 To date, there is no consensus on the relationship between the physicochemical characteristics of carbon nanotubes (CNTs) and their biological behavior; however, there is growing evidence that the versatile characteristics make their biological fate ...
Baba, Yoshinobu +5 more
core +3 more sources
Competative inhibition of renal tubular secretion of gemifloxacin by probenecid [PDF]
, 2009 Probenecid interacts with transport processes of drugs at several sites in the body. For most quinolones, renal clearance is reduced by concomitant administration of probenecid. The interaction between gemifloxacin and probenecid has not yet been studied.
Landersdorfer, Cornelia B. +6 more
core +1 more source
The analgesic effects of anti-inflammatory drugs from the point of view of different pharmacological test methods [PDF]
, 1964 1. The forms of irritation causing inflammation and pain are reviewed, with reference to the significance of histamine, serotonin and bradykinin and in particular to the interrelationship between inflammation and pain. 2.
Wilhelmi, G.
core +1 more source